Pharmacological Treatment for Social Anxiety Disorder

Schneier, Franklin R.; Bragdon, Laura B.; Blanco, Carlos; Liebowitz, Michael R.

doi:10.1002/9781118653920.ch24

Cited by 2 publications

(1 citation statement)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although several randomized controlled trials have shown that phenelzine, a monoamine oxidase inhibitor, is highly effective, its use is restricted due to side effects and dietary restrictions. MAOIs are usually reserved for SAD cases that do not respond to other treatments [ 64 ].…”

Section: Reviewmentioning

confidence: 99%

Social Anxiety Disorder: Associated Conditions and Therapeutic Approaches

Alomari¹,

Bedaiwi²,

Ghasib³

et al. 2022

Cureus

View full text Add to dashboard Cite

Social anxiety disorder (SAD) is a highly distressing chronic psychiatric disorder characterized by persistent fear of social situations in anticipation of being judged negatively by others. As shyness mimics some of the symptoms of SAD, people suffering from this debilitating disease are often underdiagnosed. It can have a devastating impact on all areas of life including academic performance, social growth, relationship status, and work performance. In recent years, research on anxiety and related disorders has proliferated due to the increased use of cognitive-behavioral models. The understanding of SAD has evolved greatly from distinguishing it from shyness to implementing modalities to comprehend the sophisticated underlying mechanism of disease prevalence and progression as well as methods to treat it. This review summarizes the concept of SAD, its epidemiology, symptoms, and diagnostic tools. Frequent comorbidities including other psychiatric disorders are also discussed. Additionally, we examine the latest evidence related to treatment options including psychotherapy and pharmacotherapy as well as recommendations for managing SAD.

show abstract

Section: Reviewmentioning

confidence: 99%